TANESHA GULLEY: Open Payments
NPI 1932743655 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$511 in 19 payments from 10 companies in 2025. Trend: 2023 $1,057 · 2024 $264 · 2025 $511
Food & beverage: $511
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 4 | $156 |
| Novartis Pharmaceuticals Corporation | 6 | $125 |
| PFIZER INC. | 2 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $40 |
| Janssen Biotech, Inc. | 1 | $35 |
| Stemline Therapeutics Inc. | 1 | $29 |
| Lilly USA, LLC | 1 | $25 |
| Myriad Genetic Laboratories, Inc. | 1 | $19 |
| Gilead Sciences, Inc. | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $14 |
Products named: Fabhalta, ENHERTU, IBRANCE, FRUZAQLA, ERLEADA, Orserdu, SCEMBLIX, VERZENIO.
Industry payments across GA — which companies pay providers there.
